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Water, is taught by thirst. 
Land - by the Oceans passed. 
Transport - by throe - 
Peace - by its battles told - 
Love, by Memorial Mold - 
Birds, by the Snow.  
 
                                                                                                      Emily Dickinson, 1830-1886 
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IV. Background 
Giardiasis 
1. Parasitology 
Giardia duodenalis (syn. G. lamblia, G. intestinalis) is a single cell parasite, inhabiting the 
small intestine. Like Plasmodium species causing malaria by infecting red blood cells, the 
genus Giardia belongs to the family protozoans [1]. The name lamblia has its origin from 
Vilem Lambl who described the trophozoite in humans in 1859, and the cyst form was 
discovered by Grassi twenty years later; however, Antony van Leeuwenhoek described the 
parasite in his own stool as early as in the 17th century [2].  
 
Six different Giardia species, characterised by differences in morphology and host 
specificity, have been described since 1952 [1, 3];  G. duodenalis infects humans as well as 
other primates, dogs, cats, livestock, rodents and some other wild animals, G. agilis infects 
amphibians, G. psittaci and G. ardeae birds and G. microti and G muris  rodents. A revision 
of taxonomy is under debate, since genetic studies and sequencing of the Giardia genome 
have revealed several genotypic groupings/assemblages that could be classified as new 
species, including assemblage A and B in G. duodenalis, which are proposed to be classified 
as G. duodenalis (=  assemblage A) and G. enterica (=  assemblage B) [1, 4]. In addition, the 
following assemblages infecting animals have been proposed to be classified as species: 
Assemblage C/D (infecting dogs and other canids): G. canis, assemblage F (cats): G. cati, 
assemblage E (cattle and other hoofed livestock): G. bovis, and assemblage G (rats) G. 
simondi. The mechanism for host specificity is not known [1]. 
 
Giardia has three morphologic forms; cysts, excyzoites and trophozoites [5]. Cysts are 
responsible for faecal-oral transmission, and are able to survive for a long period in the 
environment, especially in cold water in which experimental studies have shown survival for 
up to two months [6]. In the upper part of the small intestine, they release excyzoites 
containing four nuclei, which attach to the intestinal wall and rapidly divide into four 
trophozoites [5]. Trophozoites cause disease in the small intestine where they multiply by 
simple binary fission, though there is some evidence also of sexual reproduction [4]. The 
trophozoites have a characteristic duplication of organelles; four pairs of flagella enabling 
them to move, two identical nuclei, two median bodies and a ventral sucking disc which 
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enables it to attach to the intestinal surface (Figure 1) [1]. Trophozoites may be found in fresh 
faeces, but usually encyst, triggered by bile salts [7] or cholesterol depletion and micelle 
destruction [8], before being excreted in the stool. 
 
 
Figure 1. Giardia trophozoite showing ventral disc, flagellae, nuclei and median bodies. 
 
2. Epidemiology 
Diarrhoea is probably the most common infectious disease worldwide, and following lower 
respiratory infections the second leading cause of death due to infections; in 2004 WHO 
reported an incidence of 4.6 billion episodes and 2.2 million deaths due to diarrhoea per year, 
of these 1.8 million deaths in developing countries [9]. The most common etiologic agents 
are species among the viruses rotavirus, calicivirus, astrovirus and enteric adenovirus; the 
bacteria E. coli, Shigella, Salmonella, Campylobacter and Vibrio cholera, and the parasites 
Giardia, Entamoeba histolytica, Cryptosporidium, Cyclospora and Isospora [10].  
Infections transmitted faecal-orally are more easily spread under conditions associated with 
poverty; such as decreased access to clean water, inappropriate sewage disposal, poor 
hygiene, crowding, close contact to farm animals and low educational level. A predominance 
of bacteria and parasites as diarrhoeal pathogens in the South, and viruses in the North, 
reflects this situation [10].  
 
A prevalence of 200 million cases of giardiasis in tropical countries has been estimated by 
WHO [11]. However, decreased access to reliable diagnostic tools in socioeconomic 
underdeveloped areas makes it difficult to assess the aetiology of diarrhoea in clinical 
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practice, and reporting systems are insufficient. Such estimates are also limited by the fact 
that few case-control studies have been performed in developing countries, and the clinical 
studies that are available show that prevalence varies greatly between and within countries.  
 
Serologic studies show a high infection rate, and that people are commonly infected with 
Giardia during childhood, in developing countries. In a national serologic survey in Mexico, 
55% (1914/3461) of the samples were positive for anti-Giardia IgG, and seropositivity 
increased with age [12].  
In a study comparing populations in developing and developed areas, anti-Giardia IgG was 
found in 44% (27/62), 48% (16/33) and 46% (12/26) of adults in an Apache Indian 
reservation in Arizona, in Panama and Peru respectively, while significantly fewer (18%, 
7/41) adults in Baltimore were seropositive [13]. In Baltimore, seropositivity was low 
throughout childhood, children in Panama achieved adult levels of antibodies between nine 
and 20 years, Apache Indians by eight years of age, whereas 46% of Peruvian children were 
seropositive already by the age of six months [13]. 
Similar high prevalence was found in a cohort with low socioeconomic standard in Egypt, 
where 37% were anti-Giardia IgG positive [14]. 
 
Despite such high prevalence, giardiasis is not commonly associated with acute diarrhoea in 
hospital based studies. In different reviews, rotavirus and E. coli spp. are the most common 
causes of acute diarrhoea in both developing and developed countries [10, 15, 16]. In a study 
from India among children hospitalised due to diarrhoea, and children admitted to hospital 
for causes other than diarrhoea included as controls (n = 158 cases, n = 99 controls), the 
following pathogens were detected among cases and controls respectively: Rotavirus 43% 
and 10%, enterophatogenic E. coli 16% and 2%, norovirus 16% and 7%, and 
Cryptosporidium spp. 15% and 2%, while other agents were less prevalent, among these 
Giardia only 0.6% and 0% [17]. This study also demonstrated that molecular techniques 
increased the detection rate and changed the picture, compared to conventional diagnostic 
methods. 
Such low prevalence among hospitalised children is supported by other case-control studies, 
using children admitted for reasons other than diarrhoea as controls. In a study from Nigeria 
(n = 215 cases, n = 100 controls) Giardia was identified in only one case, and in none of the 
controls [18]. In a large study from Bangladesh (n = 2534 cases, n = 1229 controls), Giardia 
was inversely associated with diarrhoea (8% versus 18%) [19]. A significantly higher 
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prevalence among controls (23%) than cases (14%) was also found in a study from Thailand 
[20].  
These findings emphasises that when interpreting the clinical relevance of Giardia, it must be 
taken into account that identifying the parasite may be confounding rather than causal, since 
many cases are asymptomatic. In an uncontrolled study of 529 hospitalised children with 
diarrhoea from a rural area in Mozambique, Giardia was detected in 3%; however, 36% of 
the 74% cases who had malaria, which commonly causes diarrhoea, also had an 
enteropathogen (not specified) isolated. Both low level malaria parasitaemia and 
enteropathogens may be either without clinical relevance, or etiologic agents, in patients with 
diarrhoea. This illustrates the importance of case-control studies.  
 
A review of 33 mainly population based cross-sectional prevalence studies from Asia showed 
that prevalence varied greatly, also within countries [21]. Studies from Nepal, which is 
considered one of the poorest countries in the world, reported prevalence between 2% 
(elderly home) and 73% (children), and Thailand, which generally has a higher 
socioeconomic status, reported prevalence between 1% in a study from North Thailand [22] 
and 37% in a study among orphans in Pathum Thani Province [23].  
 
These serologic and clinical studies show that giardiasis is highly prevalent in many areas, 
but may not lead to severe acute diarrhoea with dehydration needing hospitalisation in most 
cases. The impact of giardiasis on the high mortality of diarrhoeal infections globally is not 
known, however the fact that Giardia in 2004 was included in the WHO’s “Neglected disease 
initiative” may hopefully strengthen the focus on this poverty related disease [24]. 
  
In Western countries, Giardia infection usually occurs after travel to endemic areas, during 
waterborne outbreaks, or through person to person spread in institutions or between risk 
groups such as homosexual men.  
Common causes of acute travellers diarrhoea are enterotoxigenic E. coli (ETEC), 
Campylobacter, Shigella and Salmonella spp, while persistent diarrhoea more often are 
caused by protozoans (Giardia, Cryptosporidium, Entamoeba histolytica, Cyclospora, 
Isospora and microsporidia spp.) [25].  
Among 17 228 travellers visiting tropical medicine clinics in Europe, 4% had acute diarrhoea 
due to Giardia, most commonly after travel to South-Central Asia (11%), in a recent report 
from the GeoSentinel Surveillance Network [26]. In a study among 328 travellers and foreign 
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residents with diarrhoea in Nepal, Giardia was diagnosed in 12%, and was more likely to 
occur in cases with diarrhoea lasting more than two weeks (27%) than in acute diarrhoea  
[27].  
In Norway, laboratory confirmed cases of giardiasis are notifiable to the Norwegian 
Surveillance System for Communicable Diseases (MSIS). About 200-300 reported Giardia 
cases have been infected abroad each year since 1990 (Table 1) [28]. Of diarrhoeal infections 
in Norway registered by MSIS in 2008, 270 were caused by Giardia, 2875 by 
Campylobacter, four by Diphtheria, 1941 by Salmonella, 134 by Shigella and 50 by Yersinia 
spp. [28]. 
 
Approximately 50 cases each year of Giardia infections acquired in Norway, have been 
registered by MSIS since 1980 (Table 1) [28]. However, in 2004 as many as 621 cases were 
registered, due to a large waterborne outbreak in Bergen in the period from August to 
December [29]. Leaking sewage pipes into the city’s water source, Svartediket (Figure 2), 
during a period of heavy rainfall, combined with insufficient water treatment, was identified 
as the source of the outbreak, and approximately 1 300 laboratory confirmed cases were 
registered. Based on the excessive number of metronidazole prescriptions made in the period, 
and taking into account that half of cases may be asymptomatic, more than 5000 cases have 
probably been infected during this outbreak [29]. This is the largest waterborne outbreak, and 
the first Giardia outbreak, registered in Norway. A total of 72 waterborne outbreaks, 
infecting 10 616 cases, have been registered in the period 1988 to 2002, 26% of these were 
caused by Campylobacter, 18% by norovirus and 46% had unknown aetiology [30].  
Waterborne outbreaks are the most important route of Giardia transmission in Western 
countries. Several factors contribute to this; experimental studies have shown that cysts may 
survive for up to two months in cold water [6], conventional water treatment methods may 
not eliminate the parasites [24], and contamination of a community water supply has the 
potential to affect a great number of people. Before the Bergen outbreak in 2004, the largest 
outbreak registered in Europe had been at the ski resort Sälen in Sweden in 1986, affecting 
>1400 people [31]. 
Waterborne outbreaks of protozoan parasites reported worldwide in the period 1955 to 2003 
have recently been extensively reviewed, and Giardia accounted for 132 (41%) of these [32]. 
Only outbreaks in Western countries have been reported, probably due to resource limitations 
and insufficient outbreak investigations in developing countries.  
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Zoonotic transmission has been reported in giardiasis [33], however, the impact of such 
transmission is not clear. Beavers were the likely source of an outbreak in USA in 1986 [34], 
but animal sources in outbreaks are not commonly reported [32]. 
Clinical case definitions are useful if parasitological testing must be avoided when 
laboratories experience capacity problems during large outbreaks. During a waterborne 
outbreak in Colorado, a Giardia case definition included illness lasting seven days or more 
combined with two or more of the symptoms diarrhoea, flatulence, foul-smelling stools, 
nausea, abdominal cramps or excessive tiredness [35]. The sensitivity and specificity of this 
definition was 88% and 73% respectively. 
 
Figure 2. Svartediket. 
 
Smaller outbreaks due to other routes of transmission have been well described from Western 
countries, although rarely. Raw vegetables and fruits contaminated with cysts from water or 
from an infected food handler are typical sources in food-borne infections [36-42]. Shellfish 
may accumulate pathogens from infected water and be a potential source of infection, and 
Giardia cysts have been identified in both oysters and mussels [43, 44]. Several outbreaks 
have been reported from child day care centres [45-48]. Transmission may also occur in 
swimming and wading pools [42, 49, 50]. Other groups at risk include homosexual men [51-
55] and persons living in institutions [47, 56].  
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Table 1. Giardia cases in Norway reported to MSIS and place of infection in the period 
1980-2009.  
Place of 
infection 1980 1990 2000 2003 2004 2005 2006 2007 2008 2009 
Norway - 7 37 25 706 162 63 55 42 37 
Unknown 13 66 19 43 621 58 35 37 26 60 
Abroad 61 255 287 254 253 208 196 198 202 156 
Total 74 328 343 322 1580 428 294 290 270 253 
 
3. Pathogenesis 
Both parasite and host factors seem to be involved in the pathophysiological processes 
causing diarrhoea, maldigestion and malabsorption in giardiasis, although incompletely 
understood.   
In vitro studies on human samples have shown that Giardia attach by its adhesive ventral disc 
to the microvillus brush border of the intestinal epithelium, and cause barrier dysfunction by 
disrupting tight junctions and inducing epithelial apoptosis [57-59]. Further have 
experimental studies shown that activated CD8 T lymphocytes produce cytokines responsible 
for shortening of epithelial microvilli, which lead to malabsorption of electrolytes, nutrients 
and water as well as inhibition of the digestive enzymes lipase, protease and disaccharidase 
[60]. Disaccharidase insufficiency, and consequently failure in splitting and absorbing milk 
lactose, causes osmotic diarrhoea characteristic for temporary lactose intolerance commonly 
seen in giardiasis. Bacterial overgrowth in the small intestine may also play a part in the 
pathogenesis of the disease [61].  
In clinical studies, inflammation and villous shortening in duodenal biopsies varies from 4% 
to 87% [62, 63], and why there is such a high variability in mucosal reactions, as well as in 
clinical manifestations, is not known. Genotypes and mixed infections have been proposed to 
be responsible for disease variability [64], but results from studies of the association between 
genotypes and severity of disease are not conclusive. An experimental study by Nash et al 
showed an association between strain variation and infectivity [65], and it seems that 
infection with a genotype less prevalent in a community induce more severe symptoms, 
however, both assemblage A and B have been associated with different symptom patterns in 
studies from different populations [19, 66-76].  
 
The host defence mechanisms are complex. Experimental studies recently reviewed [77-79] 
have shown that natural barrier mechanisms (mucus, peristalsis, proteases, lipases, bile salts, 
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intestinal microbiota and paneth cells), innate immune responses (nitric oxide, reactive 
oxygen species, lactoferrin, defensins, phagocytes, mast cells and dendritic cells) and 
adaptive immune responses, both cell-mediated as described above and humoral, are involved 
although incompletely understood. Although Giardia is not an invasive parasite, it induces a 
humoral immune reaction with production of immunoglobulines (IgG, IgM and IgA) [31, 65, 
79, 80]. Clinical studies support that adaptive immune response play a role; children in 
endemic areas and non-immune travellers seem to have a higher risk for symptomatic disease 
than those who have been exposed for a longer period of time [81], and hypo-
gammaglobulinemia is associated with chronic infection [82]. Proteins on the surface of the 
parasite, variant surface proteins (VSPs), are major immuno-reactive proteins [80], and are 
also responsible for an important defence mechanism by enabling the parasite to undergo 
variation of its surface proteins and thereby evade the host immune response [83, 84].  
 
HIV infection does not seem to be associated with more severe disease [85, 86]. Interestingly 
HIV infection stimulates the production of CD8 T-lymphocytes in the gut [87], and these 
lymphocytes are probably essential in the immune reaction against the Giardia parasite, as 
described above. 
 
4. Clinical presentation 
Experimental studies create optimal situations to study the course of an infection, although 
ethical considerations obviously limit the use of this method. Despite the questionable 
method, results from two experimental studies in humans have been reported, and are 
commonly used as references to the natural course of giardiasis. In 1953, Rendtorff reported 
results from four experiments in a controlled study of prison volunteers experimentally 
infected with Giardia cysts [88]. Of all cases receiving cysts, 53% (21/40) became infected. 
Risk for infection was associated with infectious dose: All 13 cases who received from 100 to 
1 million cysts, compared to 36% (8/22) who received 10 or 25 cysts, became infected, while 
only one cyst was not infectious in any cases. Persistent infection after at least 129 and 132 
days was found in 15% of infected cases (2/14), while 85% (12/14) spontaneously cleared the 
infection within 5-41 days (mean 18, median 13 days). Asymptomatic infection was found in 
40% (6/15), while frequent and loose stools lasting from two to four days was observed in 
60% (9/15) in these experiments [88].  
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The variation in infectivity and clinical presentation reported by Rendtorff was observed in 
another experimental study in 1987 [65]. Nash et al infected 15 healthy volunteers with two 
different Giardia strains, GS/M and Isr. Of cases infected with GS/M, 100% (10/10) became 
infected, and 50% of these became ill after a prepatent period (the time from inoculation until 
parasites are detected in stool) of 7.5 days (mean). Severity of symptoms varied; one 
volunteer had diarrhoea, flatulence, abdominal pain, anorexia, vomiting, abdominal cramps, 
headache, malaise and abdominal gurgling for six days, three volunteers had loose stools and 
milder symptoms, while one volunteer had fever and headache but no diarrhoea. Interestingly 
none of the volunteers inoculated with the Isr strain became infected; suggesting that degree 
of infectivity may be strain dependent. 
 
Both of these experimental studies are limited by few cases, and that they included adult 
males only. However, symptoms during acute infection in larger cohorts in developed 
countries have been studied during outbreaks, and these reports support that symptoms are 
variable and that the majority of infected cases remain asymptomatic.  
Among laboratory confirmed cases during an outbreak in New Hampshire in 1980, the 
following symptoms were recorded (n = 213): Diarrhoea 86%, abdominal cramps 81%, 
anorexia 65%, flatulence 58%, abdominal distension 55% and weight loss 53%. Duration of 
symptoms was 10 days (mean) and 13% were hospitalised. A community survey revealed 
that 76% of the city residents had an asymptomatic and self limiting infection during this 
outbreak [89].  
During the Bergen outbreak in 2004, 137 laboratory confirmed cases were interviewed during 
the early phase of the epidemic, and among these 90% reported diarrhoea, nausea, stomach 
pain, flatulence and foul smelling stools, 83% reported weight loss (mean 5 kg, range 1-23 
kg), 36% vomiting, 17% reported fever and 7% were hospitalised [29].  
 
Giardiasis seems to be self limiting in most cases, but a striking feature of the parasite is its 
ability to induce chronic infection, symptomatic or asymptomatic, if not treated. Rendtorff 
reported chronic infection in 15% (2/14) of experimentally infected and untreated cases [88].  
A Nordic meta-analysis reported Giardia infection in 6% of symptomatic cases (one or more 
of the symptoms vomiting, gastroenteritis, diarrhoea and abdominal pain/cramps/discomfort), 
and 3% of asymptomatic cases, in the population, supporting that chronic giardiasis is 
prevalent in non-endemic countries [90].  
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Chronic infection may present with symptoms similar to irritable bowel syndrome (IBS); a 
condition characterised by abdominal pain or discomfort, associated with altered bowel 
habits, lasting for more than 12 weeks [91]. Among 137 cases with symptoms of dyspepsia or 
IBS who satisfied the Rome II criteria [91], 7% had giardiasis in one report from Italy [92].  
 
Malabsorption in chronic giardiasis may cause chronic diarrhoea and steatorrhea, weight loss 
and nutrient and vitamin deficiencies [93].  
Vitamin B12 malabsorption, and anaemia due to Vitamin B12 and folate deficiencies, has 
been reported [94-96]. Vitamin A deficiency, a potentially severe condition since such 
deficiency is an important cause of blindness in developing countries, has also been 
documented in giardiasis; a significant improvement of vitamin A absorption was 
demonstrated after anti-Giardia treatment in one study [97].  
Osmotic diarrhoea due to lactose malabsorption is common in giardiasis, and may persist for 
weeks after eradication of the parasite [98].  
Fat and carhohydrate malabsorption has been documented in controlled clinical studies [96], 
but the role of amino acid malabsorption is unclear. Although there have been casuistic 
reports on severe protein loss and hypoalbuminaemia [99], no association between giardiasis 
and protein loosing enteropathy was found in a study in Gambian children [100].  
In a case-control study from India malabsorption syndrome was caused by Giardia in 24% 
(12/50) of adult cases compared to 8% (4/50) of healthy controls [101]. In children the 
difference was not significant (16% versus 6%) which also illustrate the problem in 
interpreting the finding of Giardia in patients from endemic areas since the infection may be 
asymptomatic.  
 
In developing countries where frequent re-infections are common [102], giardiasis 
contributes together with other infectious agents to malnutrition. Considering its high 
prevalence and the parasites’ ability to induce chronic infection and malabsorption, one 
would suspect an impact on growth in children. Since first reported in 1921, several studies 
have shown an association between severe giardiasis and such impairment [103-105]. More 
than one episode of giardiasis per year during infancy was associated with poor cognitive 
function at 9 years of age in 239 Peruvian children [106]. However, in another longitudinal 
study of 220 Peruvian children, no significant association between Giardia and nutritional 
status or diarrhoea was found [107]. 
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Also studies in asymptomatic children have shown diverging impact on growth. In one study 
from Brazil (n = 597) asymptomatic giardiasis was significantly associated with impeded 
growth [108], while studies from day care centres in western countries have not found this 
association [109], suggesting a difference in disease susceptibility between healthy and 
malnourished children.  
 
Rare extra-intestinal manifestations have been reported, probably due to immune mechanisms 
since Giardia is not invasive. These reports have been of giardiasis associated with reactive 
arthritis and synovitis [110, 111], urticaria and pruritis [112], uveitis [113] and allergy [114, 
115]. 
 
5. Laboratory diagnostic methods 
Giardiasis is diagnosed by examining stool samples by light microscopy, 
immunofluorescence assay (IFA), enzyme immunoassay (EIA) or polymerase chain reaction 
(PCR) methods. Analyses of serum or duodenal aspirates may also be performed. 
 
Light microscopy is a labour intensive method, but has the advantage of detecting additional 
parasites if present. Stool is concentrated and examined directly (wet-mount preparation) or 
permanently stained (trichrome) for cysts or trophozoites (detection of trophozoites requires 
fresh stool). Sensitivity is poor when only a single sample is analysed, particularly if there are 
few cysts or quality of microscopy is insufficient, but sporadic samples in an infected person 
may also be negative due to intermittent excretion of cysts; in one report of 91 cases all with 
three samples analysed, one, two or all three stool samples were microscopy positive in only 
23%, 22% and 55% respectively [116]. Sensitivity increases when multiple samples collected 
from separate defecations are analysed; sensitivity of  73%, 81% and 85% from analysis of 
one, two or three samples respectively have been reported (n=73) [117]. 
 
Sensitivity of microscopy increases when samples are stained with a specific anti-Giardia 
antibody coupled to a fluorescent compound (IFA). Cysts show fluorescence when examined 
under ultraviolet light in a fluorescence microscope. High sensitivity (92%-100%) and 
specificity (100%) has been reported with this method [118-120].  
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EIA also uses antibodies to detect Giardia specific antigen in stool, and these tests are less 
time consuming since the result is read after only few minutes. Several commercial rapid 
antigen tests are available, and high sensitivity (80%-99%) and specificity (>99%) has been 
reported [118, 121-124]. However, EIA was significantly less sensitive (61%) than 
microscopy in a study from the Bergen outbreak [125]. Reduced sensitivity of EIAs was 
associated with low cyst numbers and single samples in these studies. 
 
PCR is a sensitive and specific method also when there are few cysts [119, 124, 126]. In one 
study comparing PCR and IFA, sensitivity was 97% and  92% respectively (no significant 
difference) and specificity was 100% for both [119]. PCR is mainly used in research, and 
during the Bergen outbreak PCR was used to genotype and sub-genotype the Giardia parasite 
and thereby elucidate host and parasite factors [127], but the method has limited use in 
routine diagnosis.   
 
Detection of trophozoites in duodenal aspirate was previously considered a sensitive test 
when stool microscopy was negative, but studies supporting this were based on few cases, as 
shown in a review by Goka et al [117]. Larger studies have shown very low benefit from this 
test. In one study only 44% (32/73) of Giardia positive cases had positive duodenal aspirates, 
compared to 85% stool microscopy positive [117]. This finding was supported by a study 
from the Bergen outbreak were only 10% (4/40) of Giardia positive cases had trophozoites in 
duodenal biopsies [62]. 
 
Both indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA) 
may be used in detecting specific anti-Giardia antibodies [128, 129]. Serologic methods have 
been used in epidemiologic studies as described previously, but not widely in routine 
diagnostic laboratories. In endemic areas, detection of Giardia antibodies may be due to 
previous exposure, as reported in a study from Bangladesh where no association between 
sero-positivity and positive stool microscopy was found [130]. However, in areas with no 
previous exposure, serologic tests are more specific in diagnosing acute infection. In a study 
among 352 exposed cases during the outbreak in Sälen in Sweden, IgG and/or IgA antibodies 
were detected in 68% of Giardia positive cases, in 22% of Giardia negative cases and only 
among 10% of healthy controls [31]. A significant increase in sensitivity was observed when 
serum was collected more than three weeks after infection. Also in a controlled study from 
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Cuba, serology was strongly associated with positive microscopy, although sero-positivity 
increased with age which might have been due to previous exposure [131].  
 
6. Treatment 
Six classes of drugs are effective against the Giardia parasite: Quinacrine has been used since 
the 1930s, nitroimidazoles, furazolidone and paromomycin since the 1960s, benzimidazoles 
since the 1980s and the last 10 years nitazoxanide has been reported to be effective against 
giardiasis [132].  
Results from controlled clinical studies of efficacy, based on parasitological response, are 
presented in table 2 (modified from table in press by our group [133]). Recommendations of 
effective dosages based on these studies, as well as mechanisms of action and reported 
adverse effects, are presented in table 3 (modified from tables published and submitted by our 
group [133, 134]). Pharmacological aspects in anti-Giardia drugs have also recently been 
reviewed by others [132, 135, 136].  
Efficacy reported in the clinical studies are not directly comparable due to variations in the 
populations studied (age, endemicity), time until follow-up, number of stool samples 
examined, dosage of drugs and duration of treatment. In studies from endemic areas, relapse 
rates may be overestimated if duration of follow-up is too long, due to high risk of re-
infections, as reported in a study from Peru where 98% of children became re-infected within 
6 months after effective treatment [102]. However, relapses may be underestimated if follow-
up time is too short. In one study from a non-endemic area, 43% (6/14) of relapses were 
diagnosed after more than four weeks [137]. Per protocol rather than intention to treat 
analyses were presented in most of these studies, which potentially also may overestimate 
efficacy.  
 
Metronidazole has for many years been the drug of choice for giardiasis. However, single 
dose treatment with tinidazole, ornidazole or secnidazole (nitroimidazoles with long half 
lives) seems to have similar efficacy and fewer side effects. Short course treatment with 
metronidazole and other classes of anti-Giardia drugs are less effective. Nitazoxanide and 
benzimidazoles are well tolerated, and have the advantage of also being active against 
helminth infections which are endemic in developing countries [138-142], although 
benzimidazole treatment has low efficacy in some studies. Quinacrine is highly effective in 
most studies, but is not recommended as first line treatment due to potentially severe side 
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effects. The aminoglycoside paromomycin seems to be less effective than other drugs, 
although few reports are available.  
 
Available documentation of risks during pregnancy varies for different anti-Giardia drugs. 
Of the nitroimidazoles, metronidazole has been best studied. Metronidazole has shown 
carcinogenic and teratogenic effect in animal studies, and although carcinogenic effect has 
not been reported in humans, it raises concern about safety during pregnancy [143-146]. In a 
meta-analysis including 1336 women exposed during first trimester [147], and in two studies 
including 228 and 1041 pregnant women respectively [148, 149], no association with birth 
defects were found. However, malformations possibly associated with metronidazole during 
first trimester has been reported, although rarely [146, 150]. Based on these reports, 
metronidazole during pregnancy is controversial, although often recommended during second 
and third trimester, weighted against indication and availability of alternative drugs, since the 
possible risk is low [146]. Nitroimidazoles should be avoided during first trimester. 
Benzimidazoles have been widely used and recommended by WHO after first trimester in 
treatment programs among pregnant women, in order to reduce hookworm induced anaemia 
[151, 152]. In controlled studies evaluating birth defects following these programs, 
significant risk for teratogenic effects were not found [153-155]. However, the dosages used 
in anti-helminth programs are lower than recommended dosages for giardiasis, and 
experimental studies have suggested teratogenic effects [156]. One controlled clinical study 
found higher risk of major birth defects (odds ratio 1.66), although not significant, among 
women who had used mebendazole during first trimester [155]. Based on clinical reports on 
safety during second and third trimester, benzimidazoles could be used during this period, but 
should be avoided during first trimester.   
Due to mutagenic effects in animal studies, and lack of clinical studies in humans on 
teratogenic effects from furazolidone, quinacrine and nitazoxanide, these drugs should be 
avoided throughout pregnancy [157, 158].  
Paromomycin is the only anti-Giardia drug not contraindicated during first trimester [159], 
since it is poorly absorbed and therefore has negligible systemic effect. 
 
Studies on treatment refractory giardiasis are limited. In one study, albendazole in 
combination with metronidazole was effective in nine out of 10 metronidazole resistant cases 
[160]. Quinacrine combined with metronidazole or tinidazole was effective in five of six 
treatment refractory cases in one study, four of these were immunosuppressed [161]. Such 
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synergistic effect of combining metronidazole and quinacrine has also been reported in vitro 
[162]. One report  showed that nitazoxanide was effective in a patient suffering from HIV 
and metronidazole/albendazole resistant giardiasis, and the Giardia isolate from the patient 
showed the same resistance pattern in vitro and in a mouse model [163].  
 
Clinical resistance has been demonstrated for all drugs as described above, however, several 
factors may influence clinical response other than drug resistance, like inadequate immune 
response, compliance problems, reduced quality of drugs or impaired absorption due to 
vomiting and diarrhoea.  
Laboratory studies have the advantage of eliminating these factors, and in vitro resistance has 
been reported in all classes of drugs [164, 165]. Different laboratory methods have been used; 
in vivo animal studies and in vitro tests of viability, or molecular characteristics, of cultured 
human Giardia isolates or laboratory induced resistant clones. Although mechanisms of drug 
resistance are not completely understood, molecular studies have elucidated some 
characteristics. The enzyme pyruvat:ferredoxin oxidoreductase (PFOR) was downregulated 
in metronidazole resistant but not in furazolidone resistant Giardia strains, which is 
consistent with the role this enzyme has in activating metronidazole, while furazolidone 
probably is activated by nicotinamide adenine dinucleotide (NADH) and not by PFOR [166]. 
In a molecular study of genes potentially involved in resistance, laboratory induced 
nitazoxanide resistant and metronidazole resistant Giardia clones were compared to Giardia 
WB C6 wild type, and in addition to slightly reduced expression of pyruvat oxidoreductase 
(POR) and nitroreductase (NR), a gene encoding a major variant surface protein (VSP) was 
significantly reduced in both resistant clones, indicating that the parasites ability to evade 
host immune response by variable expression of surface proteins may be a target for these 
drugs [167]. The nitazoxanide resistant strain showed cross resistance to metronidazole, 
while the metronidazole resistant strain was sensitive to nitazoxanide in this study [167]. 
Cross resistance found in vitro between other anti-Giardia drugs has also been reported; 
furazolidone resistant strains induced more easily quinacrine resistance in one study [168], 
and albendazole resistance was more readily induced in a furazolidone resistant strain in one 
report [169].  
Drug susceptibility testing is not routinely used, although relatively simple systems for 
resistance testing are commercially available and could be used in surveillance of drug 
resistance in giardiasis [170].  
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Other drugs have been studied experimentally, and have recently also been reviewed by 
others [132, 171]. The following compounds have shown anti-Giardia effect in vitro or in 
animal studies: Bithionol, dichlorophene and hexachlorophene [172], pyrimethamine and 
chloroquine [173], the tricyclic antidepressant drug chlorimipramine [174], sodium fusidate 
which also has the advantage of not being terotegenic [175], ronidazole, satranidazole, 
fexinidazole, flunidazole and nimorazole (5-nitroimidazoles), nitrofurantoin and niridazole 
[176], mefloquine, doxycycline and rifampin [177], ivermectin [178], fenbendazole [179], 
ciprofloxacin [180], bismuth subcitrate [181], thiosemicarbazone [182], new benzimidazoles 
[183-185], ethyl-phenylcarbamates [186], menadione which also killed cysts [187], the 
naturally derived  saturated fatty acid dodecanoid (lauric) acid [188], nocodazole and 
colchicine [189], silymarin [190], new thiazolides [191], disulfiram [192] and azithromycin 
[193].  
Controlled clinical trials of experimental drugs against Giardia have shown some promising 
results. Bacitracin zinc had anti-Giardia effect both in vitro [194] and in vivo; one clinical 
study reported 95% (20/21) efficacy [195].  In a study from Cuba, chloroquine 10mg bid for 
five days cured 86% [196], and chloroquine has also shown anti-Giardia effect  in vitro [173, 
197].  D-propranolol has demonstrated inhibition of growth and motility of the protozoan in 
vitro [198], and clinical effect in a metronidazole resistant case has been reported [199]. The 
bee glue preparation propolis inhibited growth in vitro in one report [200], and in a clinical 
study treatment for 20 days cured 80% [201]. Ozone have shown anti-Giardia effect in vitro 
in different studies [202, 203], and in a clinical trial ozonized sunflower oil cured 64% [204].  
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Table 3. Drugs active against Giardia infection; mechanisms of action, recommended 
dosages and side effects (modified from [133, 134]).  
Drug Mechanism Adverse events Recommended dosage1  Other 
Adults Children 
Five-nitroimidazole compounds  
Metronidazole 
 
 
 
Reductive activation of nitro 
group, by ferredoxin and the 
enzyme PFOR.  
Anti-parasitic effect: 
-Bind to DNA 
-Produce toxic radicals 
-Inhibit trophozoite 
respiration 
 
GI discomfort, metallic taste, 
disulphiram-like effects. Headache, 
vertigo, insomnia, irritability, 
neuropathy, seizures. Rash. 
Reddish-brown urine. Transient 
elevation of transaminases. 
Leukopenia. Pancreatitis, hepatitis, 
cholangitis (rare). 
Metronidazole less tolerated than 
the other 5-nitromidazole 
compounds. 
200 mg tid x 7 d
500 mg sd3  x 10d 
500 mg tid x 5 d 
15 – 202 x7 d  
22.52 x 5 d 
 
First line 
treatment. 
Metronidazole  
efficacy low when 
shorter course 
than 5 days, the 
other compounds 
effective as single 
dose due to longer 
half life.  
Tinidazole  
 
 
1.5 – 2 g sd  504 sd (syrup 
available) 
Ornidazole  
 
1 – 2 g sd  20 – 404 sd  
Secnidazole  
 
2 g sd  304 x 1 d 
 
Nitrofuran derivatives 
  
Furazolidone  Possibly reductive activation 
by the enzyme NADH 
oxidase, and production of 
toxic nitro radicals which 
damage  the parasites 
functional organelles 
including its DNA. 
Nausea, vomiting, diarrhoea. 
Haemolytic anemia in neonates and  
in G6PD-deficiency. Disulphiram-
like activity. Interaction with MAO 
inhibitors. Brownish urine. 
100 mg qd x10 d 65 x 10 d 
(syrup 
available) 
Should not be 
given to neonates 
or breastfeeding 
women, due to 
risk of haemolytic 
anemia. 
 
Benzimidazoles    
Albendazole  Inhibits cytoskeleton 
polymerization and impaire 
glucose uptake by binding to 
the parasites -tubulin 
cytoskeleton. 
Usually well tolerated. Nausea, 
vomiting, diarrhoea, epigastric 
pain. 
400 mg sd x 5d 104 x 5 d Also effective 
against helminths. 
Albendazole 
effective in 
treatment 
refractory cases in 
combination with 
metronidazole. 
 
Mebendazole  Usually well tolerated. Transient 
abdominal pain. 
100 - 200 mg bid - tid x 1 – 5 d 
(Optimal dose and duration 
unclear)  
 
Acridine derivatives    
Quinacrine  Not fully understood. 
Possibly inhibition of 
nuclein acid cyntesis by 
binding to DNA, or 
decreased oxygen 
consumption due to 
interference with the enzyme 
NADH oxidase. 
Potentially severe side effects. 
Vomiting, bitter taste, nausea, 
headache. Yellow discoloration of 
skin, urine or sclerae (reversible). 
Urticaria, exfoliative dermatitis, 
exacerbation of psoriasis. 
Haemolysis in G6PD-deficiency. 
Psychosis. 
 
100 mg tid x 5 d 82 x 5 d Effective in 
treatment 
refractory cases, 
alone or in 
combination with 
other drugs.  
 
Amoniglycosides    
Paromomycin Interaction with 50S and 30 
S ribosomal subunits leads to 
misreading of mRNA, and 
thereby inhibits the parasites 
protein synthesis. 
 
Usually well tolerated. 
Gastrointestinal discomfort. 
500 mg tid x 10 d 252 x 10d Regarded as safe 
in pregnancy.  
 
5-nitrothiazolyl derivatives     
Nitazoxanide  Not fully understood. Anti-
parasitic effect after 
reductive activation. 
Inhibition of parasite 
nitroreductase G1NR-1. 
 
Usually well tolerated. Abdominal 
pain, diarrhoea, vomiting, 
headache, yellowish urine. 
 500 mg bid x 3d 7.54 bid x 3 
(syrup 
available) 
Also effective 
against helminths 
and some bacterial 
enteric infections. 
Effective in 
metronidazole 
resistant infection. 
 
Abbreviations: GI, gastrointestinal; Sd, single dose; PFOR, Pyruvate ferredoxin oxidoreductase; G6PD, Glucose-6-phosphat-dehydrogenase; 
NADH, Nicotinamide adenine dinucleotide; DNA, Deoxyribonucleic acid; mRNA, messenger ribonucleic acid; bid, twice daily; tid, three 
times daily; qd, four times daily; d, days; g, gram.   
1Based on results from clinical studies (Table 2).  
2mg/kg/day, divided into three doses. 
3One day duration of sd if not other is stated. 
4mg/kg. 
5mg/kg/day, divided into four doses. 
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V.     Aims of the study 
To evaluate efficacy of a treatment ladder, and genetic characteristics, in treatment refractory 
giardiasis after an outbreak in Bergen, Norway in 2004. 
 
To investigate if cases with persistent abdominal symptoms after Giardia infection, and no 
detectable Giardia parasites in stool, suffered from chronic, cryptic giardiasis.  
 
To investigate the prevalence of fatigue and abdominal symptoms, and factors associated with 
such symptoms, two years after the Giardia outbreak. 
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VI. Summary of papers 
A. Paper 1   
Metronidazole is the only drug licensed against Giardia infection in Norway. The objectives 
of this study were to evaluate the efficacy of three different anti-Giardia treatment regimens 
in cases who had not responded to metronidazole treatment, and to compare genetic 
characteristics of the parasites.  
This was a clinical observational study among cases who had been infected with Giardia 
during the outbreak in Bergen in autumn 2004, and who experienced chronic, treatment 
refractory infection. Among 1268 laboratory confirmed cases registered during the outbreak 
in August-December 2004, 120 cases were referred to our out patient clinic due to protracted 
abdominal symptoms. Of these, 42 cases still had Giardia cysts in stool samples after mean 
2.2 (range 1-3) courses of metronidazole, and 38 of these were treated according to a 
standardised treatment ladder in the period between January 2005 and December 2006.  
 
All patients were treated with albendazole 400 mg bid in combination with metronidazole 250 
mg bid for one week. Those who did not respond to this regimen were treated with 
paromomycin 500 mg tid for one week. Those who failed on both these regimens were treated 
with quinacrine 100 mg tid in combination with metronidazole 750 mg tid for three weeks. 
Treatment efficacy was based on parasitological response defined as seven microscopy 
negative stool samples up to four weeks after the end of treatment. Clinical symptoms and 
adverse events were evaluated at baseline and four weeks after treatment. 
Giardia isolates were available from 45% of cases (17/38) for characterisation by PCR and 
sequencing at the gdh and -giardin genes respectively.  
 
Albendazole in combination with metronidazole was effective in 79% (30/38), paromomycin 
was effective in 50% (3/6), and quinacrine in combination with metronidazole was effective 
in 100% (3/3) of the cases. Discoloration of skin, confusion, nightmares, dizziness and nausea 
were recorded in the quinacrine/metronidazole group, and mild hair loss was reported by one 
patient in the albendazole/metronidazole group. Except for the episode of mild hair loss, no 
unexpected or severe side effects were recorded in any of the groups.  
Sequencing of PCR products revealed that all cases had Giardia cysts of genotype gd-ber3 at 
the gdh gene and BG-ber2 at the -giardin gene, while previously published sequence profiles 
from the peak of the outbreak were more heterogenous. 
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In this study, albendazole and quinacrine, both in combinations with metronidazole, were 
effective against metronidazole refractory giardiasis, while paromomycin seemed to be less 
effective. Particular sub-genotypes may be associated with treatment refractory infection in 
this cohort. 
 
B. Paper 2   
The aim of this study was to evaluate if Giardia negative patients, referred to our outpatient 
clinic due to protracted abdominal symptoms after the Bergen outbreak in 2004, suffered from 
cryptic and metronidazole refractory chronic giardiasis. 
 
This was a prospective randomised open clinical study. The included patients had been 
exposed to contaminated water and had clinical giardiasis during the outbreak, and after 
treatment with one to three courses of metronidazole for five to ten days, all cases had more 
than three microscopy negative stool samples and one negative faecal antigen test. 
Based on reports on synergistic anti-Giardia effect of metronidazole and albendazole 
combination treatment as described in paper 1, patients in one arm were treated with 
albendazole 400 mg bid and metronidazole 250 mg tid for seven days (A/M). Based on the 
hypothesis that an illness similar to post-infectious tropical sprue may be one possible 
explanation for protracted abdominal symptoms and weight loss, patients in the other arm 
received tetracycline 250 mg tid and folic acid 5 mg once daily for 28 days (T/F). 
Abdominal symptoms were reported by the patients on a written questionnaire at baseline, at 
the end of treatment, one month after treatment and finally one year after treatment. The 
primary endpoint was global improvement of symptoms one month and one year after 
treatment. Secondary endpoints were improvement of nausea, bloating, abdominal pain, 
diarrhoea, constipation and anorexia recorded on a scale from zero to ten, and changes in 
blood inflammation and malabsorption parameters. 
Symptom scores were analysed regarding time and treatment using mixed linear modelling. 
 
A total of 25 cases were included in the study.  Blood tests taken at baseline and after one 
month were not significantly changed. At the end of treatment, total symptom score improved 
in both groups, although significantly only in the T/F group, while bloating decreased 
significantly in both groups at this point.  
 29
One month after treatment, 23% (3/13) in the T/F group and 8% (1/12) in the A/M group 
reported global symptom improvement. However, after one year total symptom scores were 
unchanged from baseline in both groups.  
 
C. Paper 3   
The objective of this study was to evaluate the prevalence of fatigue and abdominal symptoms 
among cases who had been infected during the Bergen outbreak in 2004, two years after.  
 
Inclusion criteria was laboratory confirmed giardiasis during the Bergen outbreak. All 1262 
Giardia–positive cases registered in the period of October 2004 to June 2005, received a 
mailed questionnaire in August 2006 (Appendix).  
The following questions regarding fatigue and abdominal symptoms, respectively, were used 
in the statistical analyses: “Do you have abdominal symptoms now that you did not have prior 
to the Giardia infection?” (no/unsure/yes, dichotomized into no/unsure vs. yes) and “Do you 
have problems with fatigue?” (less or same as usual/more than usual/much more than usual). 
The last two answer options were defined as fatigue. 
The association between fatigue and abdominal symptoms, gender and age, was investigated 
by simple and multiple ordinal logistic regression analyses using SPSS.  
 
Among the 1017 (81%) respondents, 64% were women and the median age was 31 years, 
compared to 61% and median 30 years among all 1262 cases.  
Fatigue and abdominal symptoms was reported by 41% (419/1017) and 38% (389/1017), 
respectively, and 25% (253/1017) reported both symptoms.  
Increasing age was significantly associated with fatigue (p < 0.001) in all analyses. Female 
gender was significantly associated with fatigue in the simple (p = 0.038) but not in the 
multiple regression analyses. Neither age nor gender was significantly associated with 
abdominal symptoms. A significant association between fatigue and abdominal symptoms (p 
< 0.001) were found in all analyses, and neither gender nor age interacted with this 
association. 
 
A high level of post-infectious fatigue and abdominal symptoms, not previously reported in 
giardiasis, were found in this study. 
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D. Paper 4 
This paper describes risk factors associated with post-Giardia fatigue and abdominal 
symptoms two years after the Bergen outbreak.  
 
Inclusion criteria and questionnaire (Appendix) used were the same as described in paper 3, 
and in this study the data were further analysed with respect to risk factors.  
Number of treatment courses, delayed education and sick leave were used as indices of 
protracted and severe Giardia infection in the statistical analyses, and the sub-cohort of 
treatment resistant cases described in paper 1 were also included in these analyses. Previous 
abdominal problems, symptoms during infection, age and gender were also evaluated as 
possible risk factors. Simple and multiple ordinal logistic regression analyses were used to 
investigate the association between these possible risk factors (explanatory variables) and 
degree of abdominal symptoms and fatigue (response variables). 
 
More than one course of anti-Giardia treatment and delayed education, were significantly 
associated with both fatigue and abdominal symptoms in all analyses. In the multiple 
regression analysis, female gender, bloating at the time of infection and treatment refractory 
infection were associated with abdominal symptoms. Age, previous abdominal problems 
without seeking health care, malaise at the time of infection and sick leave were associated 
with fatigue in the multiple regression analysis.  
 
Indices of protracted and severe Giardia infection were associated with post-infectious fatigue 
and abdominal symptoms in this study. 
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VII. Main results and discussion 
Paper 1. Treatment-ladder and genetic characterisation of parasites in refractory 
giardiasis after an outbreak in Norway 
The paper describes high efficacy of combination treatment of albendazole or quinacrine in 
combination with metronidazole, respectively, and less efficacy of paromomycin, in 
metronidazole refractory chronic Giardia infection. Synergistic effect of metronidazole and 
albendazole has been reported from a randomised trial of metronidazole resistant cases [160], 
and our study is in line with this finding. Randomised trials on quinacrine and paromomycin 
in treatment refractory giardiasis have not been performed, although a case series among 
resistant cases successfully treated with quinacrine combined with nitroimidazole support our 
findings [161]. This study was an observational study using a treatment-ladder, while a 
randomised study design would have strengthened our findings. Metronidazole is the only 
anti-Giardia drug licensed in Norway, and delays in availability were different for the 
different drugs. A randomised study would have delayed treatment in patients with 
bothersome symptoms, and was therefore not performed for ethical reasons.  
The three regimens can not be compared, since patients treated in the late steps in the ladder 
had clinically more multi-resistant parasites than patients treated in the first step. The efficacy 
of paromomycin and quinacrine/metronidazole should also be interpreted with care due to low 
number of cases.  
 
In order to study genetic characteristics of the parasites, two gene sequences were analysed 
and the parasites were identical at these sequences, which was different from the picture 
during the peak of the outbreak, where 10 different sub-genotypes were described [244]. This 
leads to the hypothesis that the sub-genotypes found in our study may have been responsible 
for more virulent or resistant infection. The genes involved in metronidazole resistance are 
not fully characterised. Results from molecular studies show that such resistance may be 
mediated by altered gene expression, possibly involving reduced expression of the genes 
encoding for PFOR and VSPs [167], however, this remains to be further investigated. The 
sub-genotypes characterised in the present study do not fully explain metronidazole 
resistance, since these sub-genotypes were also found in cases diagnosed subsequent to the 
outbreak who responded to metronidazole treatment [127]. However, if these strains were 
more virulent, resistant or infective than other strains, they may have persisted longer in the 
environment, and thereby infected cases subsequent to the outbreak and also induced chronic 
infection. The host-parasite interactions in giardiasis are not fully understood, as previously 
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discussed, and other factors explaining chronic infection in this cohort are probably also 
involved. This is underlined by the fact that one of the more resistant cases in this study, who 
finally responded to quinacrine/metronidazole, had clinically significant IgA deficiency, an 
immunological disorder known to predispose to chronic giardiasis [82].  
 
Paper 2. Effects of albendazole/metronidazole or tetracycline/folate treatments on 
persisting symptoms after Giardia infection: A randomized open clinical trial 
After the Bergen outbreak all patients referred to our out patient clinic with chronic infection, 
diagnosed by detection of cysts in stool, were successfully treated as described above. 
However, approximately half the cases referred due to protracted abdominal symptoms did 
not have detectable parasites in stool. Chronic infection and fluctuation in cyst excretion is  
well described in giardiasis [88], and could be a possible explanation for symptoms in these 
cases.  
Diarrhoea and weight loss were common during the outbreak [29], which are characteristic 
symptoms of malabsorption. Important differential diagnoses to malabsorption in addition to 
giardiasis are Cryptosporidium infection, celiac disease, lymphoma and tropical sprue [93]. 
Cryptosporidium had been excluded by negative faecal antigen tests, and anti-endomysial and 
anti-tissue transglutaminase antibodies as well as duodenal biopsies did not reveal celiac 
disease or lymphoma as etiologic agents [62]. Tropical sprue is a syndrome of undefined 
aetiology, characterised by small intestinal mucosa damage and often severe malabsorption of 
vitamine B12, folate and fat, following an episode of acute diarrhoea [93]. The name refers to 
that the condition is geographically restricted to specific areas in the tropics; it is much more 
common in Asia than in South America and Africa. Antibiotics may be effective, which 
support an infectious aetiology. The cases in our cohort had not travelled abroad, but the 
hypothesis was that a similar condition, involving bacterial agents, could explain the 
symptoms. 
 
This study described that treatment directed against chronic giardiasis and tropical sprue, 
among cases with persistent abdominal symptoms following giardiasis, had no effect on 
symptoms one year after treatment.  
The temporary symptom reduction reported may have been due to anti-inflammatory effect, 
or effect on gut microbial flora, of both treatments. The difference in temporary symptom 
reduction seen between the groups may be explained by the longer duration of T/F treatment. 
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It is not known if reporting of symptoms were influenced by cases expecting to improve 
during treatment, which would have been elucidated if a placebo group had been included. 
The reason for not including a placebo group was mainly that extending to three arms would 
have been more resource and time consuming in a clinical setting, and would have delayed 
treatment in the symptomatic group.  
Taking these limitations into account, the lack of change in symptoms after one year, leads to 
the conclusion that chronic giardiasis, or a tropical sprue-like illness, did not explain 
symptoms in this cohort. 
 
Paper 3. High rate of fatigue and abdominal symptoms 2 years after an outbreak of 
giardiasis 
During the Bergen outbreak, protracted symptoms after infection, among Giardia negative 
patients, were reported both in primary health care and among cases referred to our outpatient 
clinic [62, 245]. Of those referred, all Giardia positive cases had been successfully treated as 
described in paper 1, while the majority were Giardia negative but still complained of IBS-
like symptoms and fatigue [62]. Chronic infection could hypothetically explain protracted 
symptoms [88], but this was excluded among referred cases as described in paper 2. Extensive 
work-up among all referred cases, including stool culture and microscopy, endoscopy and 
blood tests, did not reveal the cause of IBS-like symptoms and fatigue, and on this 
background the present study of post-infectious symptoms among all cases was initiated.  
 
We reported fatigue in 41% and IBS-like symptoms in 38% of patients two years after the 
outbreak, among all laboratory confirmed cases. Such complications are not previously 
reported after giardiasis, but post-infectious fatigue and IBS are well described complications 
after other infections [246, 247], which support this finding. However, the prevalence of such 
symptoms is high in the general population, and both age and gender are possible risk factors; 
in Norwegian population studies, fatigue has been reported by 22% [248], and IBS by 10% 
[249]. It is therefore an important methodological limitation in the present study that an age 
and sex matched control group was not included.  
Another limitation is the recording of symptoms, especially fatigue which was recorded by 
one question only (Appendix). Validated questionnaires have been developed for chronic 
fatigue [250], and Rome diagnostic criteria are widely used for IBS [91]. Use of validated 
questionnaires would have strengthened our findings. However, these forms are extensive, 
and the high response rate (81%), which is a strength of our study, is probably partly 
 34
explained by the short two-page questionnaire used. It is likely that abdominal symptoms 
recorded in our study are similar to IBS, since the questions used have been used in recording 
severity of IBS previously [251], and 81% in a sub-group of cases from the Bergen outbreak 
fulfilled the Rome II criteria for IBS [115]. 
 
The inclusion criteria may have created a selection bias. Only laboratory confirmed cases 
were included, to ensure that only Giardia cases were investigated. However, this selects 
cases who visited their doctor due to symptoms during giardiasis, and could exclude cases 
with milder symptoms and cases with a less care seeking behaviour. In a large case-control 
study (n = 4388) among  fatigue syndrome and IBS patients, both these patient groups 
consulted their GP more often, and received more often sickness certificates, than controls 
within three years prior to diagnosis [252]. Many cases will have experienced a self-limiting 
infection, and if they hesitated in visiting their doctor they may have become well without 
treatment. More women were registered during and subsequent to the outbreak [253], and this 
could reflect that women seek medical care earlier, and that more men experienced a self-
limiting infection, although water drinking habits has also been suggested to explain this 
difference.  
Co-morbidities were not registered in our study, and it is possible that patients with co-
morbidities would visit their doctors earlier than healthy, young individuals. A strong 
association between psychiatric disorders and chronic fatigue has been reported in population 
based studies [254], and other conditions prior to diagnosis have also been found more 
frequently in chronic fatigue compared to controls [252]. These possible confounding factors 
could have been elucidated if we had recorded information on co-morbidity and previous 
health in our study.  
 
The possibility that any economical loss could be compensated by the health system creates a 
risk for over-reporting of symptoms. This could have been elucidated by using application for 
compensation as explanatory variable in the analyses, but this was not recorded in this study. 
Finally, recall bias is an obvious limitation, which also has been discussed in the paper. 
 
Taking these limitations into account, our finding of a high level of fatigue and IBS-like 
symptoms, which often lead to pronounced symptoms and reduced quality of life among 
young individuals, should lead to further investigations on post-infectious complications in 
giardiasis. 
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Paper 4. Severity of Giardia infection associated with post-infectious fatigue and 
abdominal symptoms 
Severity of infection has been reported as an important risk factor for both post-infectious 
fatigue and IBS following different infections [246, 255]. To study if this was the case also in 
giardiasis, we defined factors that hypothetically could indicate severity (number of treatment 
courses, treatment refractory infection, delay in education progress and sick leave), and used 
these as explanatory variables in the statistical analyses. We found a significant association 
between several of these indices of severity and fatigue and abdominal symptoms.  
The factors defined as indices of severity have several limitations. Several treatment courses 
may have been a sign of treatment refractory and protracted infection, but also a sign of PI-
IBS if stools were not controlled at follow-up, which often was the case during the outbreak 
due to reduced laboratory capacity. However, it is likely that patients experienced a change in 
symptom pattern when the parasites were cleared, especially disappearance of the foul smell, 
and then additional treatment courses may not have been requested. A further limitation of 
several treatment courses as an index of protracted infection is that some cases have been 
infected for several months before they received treatment, due to late detection of the 
outbreak [29], while those who became ill when the outbreak was well known from the media 
may have received treatment immediately. Nevertheless, the finding of several treatment 
courses as a risk factor was supported by that laboratory confirmed treatment refractory and 
chronic infection in a sub-group (paper 1) was associated with post-infectious abdominal 
symptoms as well. These findings suggest that treatment resistant parasites may have been 
more virulent and caused more severe infection during this outbreak. 
 
Both delays in education progress and sick leave may have been caused by post-infectious 
complications rather than protracted and severe infection, and this has been discussed. 
However, it is probable that cases were unable to work or study due to severe symptoms 
during infection, while the post-infectious complications developed more slowly or 
fluctuated, which also is our clinical impression from referred cases. If sick leave or delayed 
education progress were due to giardiasis, they are good indices of severity of infection, since 
many cases experience mild symptoms during infection which would not influence their work 
[88].   
Some questions were designed in a way that did not include all respondents (Appendix), and 
it is not clear whether these limitations in the questionnaire have influenced the outcome of 
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the multiple regression analyses. The category “not recovered” was included in the categorical 
variable “Treatment courses” to avoid loosing cases, although this category could reflect the 
response variables. However, when the analyses were performed without this variable, other 
risk factors remained significant. 
 
Frequent re-infections in endemic regions [102], and the fact that giardiasis most often is self-
limiting [88], have led to recommendations of not to treat in many cases [132]. However, if 
our findings are causal, early detection and treatment of Giardia infection could be important 
also in order to avoid protracted infection, and thereby prevent post-infectious fatigue and 
abdominal symptoms. 
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VIII. Proposals for future studies 
 Molecular studies on resistance in treatment refractory cases. 
 
 Prospective, randomised studies on combination treatment in refractory giardiasis. 
 
 Controlled, long term follow up studies using validated questionnaires on prevalence 
of post-infectious fatigue and IBS. 
 
 Prospective, controlled studies on fatigue and IBS after severe versus mild or 
asymptomatic infections, using validated questionnaires, clinical evaluation and 
intestinal biopsies evaluating mucosa damage. 
 
 Clinical, epidemiologic and molecular studies in collaboration with centres in endemic 
countries to evaluate manifestations among cases experiencing frequent re-infections 
and co-infections compared to non-immune cases in western countries. 
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IX. Conclusions 
Metronidazole in combination with albendazole or quinacrine, were effective and safe 
treatments in a cohort of metronidazole refractory giardiases, while paromomycin was 
effective in only 50%; however, efficacy from the different treatment regimens can not be 
compared due to limitations in the design of the study.  
 
The Giardia parasites causing metronidazole refractory infection were closely related 
compared to the sub-genotypes at the beginning of the outbreak, indicating that parasite 
factors may have been partly responsible for treatment resistance during this outbreak. 
 
Persistent abdominal symptoms in a cohort of Giardia-negative cases after the outbreak were 
not due to chronic Giardia infection or to a tropical sprue-like infection. 
 
Post-infectious fatigue and IBS-like symptoms, not previously described in giardiasis, were 
found in 41% and 38%, respectively, among all laboratory confirmed cases during the Bergen 
outbreak two years after clearing the Giardia infection. 
 
A strong association between fatigue and IBS-like symptoms suggest that these symptoms 
may be manifestations of the same post-infectious condition following giardiasis. 
 
Indices of severe and protracted Giardia infection were associated with post-infectious fatigue 
and IBS-like symptoms two years after. 
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